RE:RE:RE:RE:Who can get to the bottom of things?It seems to me that Dr. Deborah Rathjen has been downplaying xB3 so badly that it supports the thought that xB3 will be sold off to a third party after the deal is done. You wouldn't want those Midatech and other shareholders to gain an understanding of what xB3 is really worth. And who cares what the old Bioasis shareholders think. They don't enough to anything about anything.
As a bonus, Dr. Deborah Rathjen may be included in the sale of xB3.
Free, with a partnership coming after, a reward for her immense expertise, good behaviour.and just because.
jd